Antifungal susceptibility testing and resistance
- DOI:
- 10.1093/med/9780198755388.003.0047
The availability of choice of systemically active antifungal agents and the proliferation in the number of fungal species implicated in invasive disease have meant that clinicians are increasingly looking for guidance from clinical laboratory results to help select the most appropriate agent. There are now well-established and predictable patterns of innate in vitro resistance to one or more antifungal agents associated with many yeast and mould species. This chapter provides definitions for the most frequently used terminology and outlines some of the issues surrounding antifungal susceptibility testing with yeast and mould isolates. Reference methods published by the Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are discussed. Both innate and emergent antifungal drug resistance are increasingly recognized as limiting factors in the selection of antifungal agents, and the epidemiology and mechanisms of resistance are described for each of the major classes of antifungal agent.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
